Date:11/11/2009

zole is a well-known Proton Pump Inhibitor (PPI) which is widely utilized to treat gastroesophageal reflux disease (GERD). Omeprazole is on China's National Medical Reimbursement Insurance List, allowing insured patients to receive reimbursement for the cost of injections, and has been included in the WHO (World Health Organization) Model List of Essential Medicines in March 2009. Sales of Omeprazole kicked off in the fourth quarter of this year. -- On September 30, 2009, China Pharma Holdings stock began trading on NYSE/AMEX under the symbol: CPHI. -- The Company participated in the following conferences and meet institutional investors throughout the events. -- Roth China Conference, held October 12-14, 2009, in Miami Beach, FL. -- Rodman & Renshaw Annual Global Investment Conference, held September 9-11, 2009, in New York City. -- Maxim 3rd Annual Growth Conference, held September 29, 2009, in New York City.

Financial Guidance

CPHI is reiterating its guidance of 20% top line growth for the full year 2009, on a year over year basis.

China Pharma's President and CEO, Ms. Zhilin Li, stated, "We are pleased to report a quarter with continued revenue growth supported by increased marketing efforts and distribution expansion. In the third quarter of 2009, several newly-launched products started to show great potential in sales. Our third quarter performance also reflects the significant progress to manage our receivables collection efforts. With regards to our recent listing onto the NYSE Amex, we feel proud to have reached this important milestone. Our success of this listing underscores our commitment to generating long-term value for our shareholders."

Conference Call

The Company will hold a conference call at 8:00 am ET on November 12, 2009 to discuss fiscal third qua
'/>"/>

SOURCE China Pharma Holdings, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. China Sky One Medical, Inc. Announces Conference Call to Discuss Third Quarter 2009 Results
2. China Medicine Announces Conference Call to Discuss Third Quarter 2009 Results
3. Monsanto Opens First Biotechnology Research Center in China
4. Chinas Research Output More Than Doubled Since 2004, Thomson Reuters Study Reveals
5. China-Biotics, Inc. Appoints New Vice President
6. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
7. China Biologic Named to Forbes Magazines Fifth Annual List of Asias 200 Best Under a Billion
8. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
9. China Medical Technologies Announces the SFDA Approval for its SPR System
10. China Integrated Energy, Inc. Announces Preliminary Third Quarter Financial Results and Increases Full Year Guidance
11. China Integrated Energy, Inc. Announces Eight Million Share Public Follow-On Offering